Predictors of Speech Motor Sequence Learning in Neurological Disorders

神经系统疾病中言语运动序列学习的预测因素

基本信息

项目摘要

Project Summary For the many Americans living with neurogenic speech disorders, the simple task of talking—producing a sequence of speech sounds—presents significant barriers in daily life. Therefore, learning to produce new sound sequences (such as those in a difficult word) is a central component of speech rehabilitation. However, the mechanisms underlying speech motor sequence learning are poorly understood despite the critical importance of this process to speech therapy. Accurate speech production involves both a phonological encoding stage to plan and sequence upcoming sound units (i.e., phonemes) and a motor programming stage to transform the planned phonemes into precise motor movements. It remains unclear how these two stages interact to support the learning of new speech sequences. The primary objective of this proposal is to differentiate the roles of phonological planning and speech motor programming processes during speech motor sequence learning in patients with primary progressive aphasia (PPA). PPA is a category of neurodegenerative disease in which the location and degree of brain atrophy is closely tied to specific speech-language impairments in each individual, and thus allows for relatively precise localization of speech-language function. Patients with PPA may have isolated phonological impairment (e.g., logopenic-variant PPA) or motor programming impairment (e.g., progressive apraxia of speech), or may have relatively intact speech. In this project, participants will complete a two-day learning paradigm where they will practice novel syllables containing non-native consonant clusters that do not occur in English. Improvements in the accuracy and speed of practiced consonant clusters will be compared to their performance on syllables containing untrained non-native consonant clusters. The central hypothesis, based on the GODIVA model of speech sequencing, is that phonological learning should result in reduced utterance duration while motor program learning should result in improved accuracy. This project will test this hypothesis through two specific aims: 1) determine the behavioral predictors of speech motor sequence learning abilities, and 2) establish the neural correlates of these abilities. Aim 1 will test the relationship between learning measures and common clinical measures of phonological and motor programming ability. Aim 2 will analyze the relationship between learning measures and the degree of cortical thinning in phonological and motor programming brain regions. This study will further our knowledge of the mechanisms involved in speech motor sequence learning, in line with the NIDCD mission to advance our understanding of normal and disordered speech and improve the lives of individuals with communication disorders. This proposal will also provide crucial training in areas including structural neuroimaging methods and neurodegenerative speech disorder research that are essential for the trainee’s successful transition to an independent research career.
项目摘要 对于许多患有神经性语言障碍的美国人来说,说话的简单任务--产生一个 言语声音序列--在日常生活中存在重大障碍。因此,学习产生新的声音 序列(例如在困难单词中的序列)是言语康复的中心组成部分。但 尽管言语运动序列学习的重要性, 到语言治疗。准确的言语产生包括语音编码阶段, 规划和排序即将到来的声音单元(即,音素)和运动编程阶段,以将 将计划好的音素转化为精确的运动动作。目前尚不清楚这两个阶段如何相互作用,以支持 学习新的语音序列。本建议的主要目的是区分以下方面的作用: 言语运动序列学习中的语音规划和言语运动编程过程 原发性进行性失语(PPA)患者。PPA是一类神经退行性疾病,其中 脑萎缩的位置和程度与每个个体的特定言语-语言障碍密切相关, 从而允许语音语言功能的相对精确的定位。PPA患者可能有 孤立的语音障碍(例如,逻辑开放变异PPA)或运动编程障碍(例如, 进行性言语失用症),或者可能具有相对完整的言语。在这个项目中,参与者将完成一个 为期两天的学习模式,他们将练习包含非母语辅音群的新音节, 在英语中不出现。提高练习辅音群的准确性和速度将是 与它们在含有未经训练的非母语辅音簇的音节上的表现相比。中央 基于GODIVA语音排序模型的假设是,语音学习应该导致 减少的话语持续时间,而运动程序学习应导致提高的准确性。该项目将 通过两个具体目标来检验这一假设:1)确定言语运动序列的行为预测因子 学习能力,以及2)建立这些能力的神经相关性。目标1将测试 学习测量和语音和运动编程能力的常见临床测量。目标2将 分析学习测量与语音和听觉皮层变薄程度之间的关系, 运动编程大脑区域。这项研究将进一步加深我们对言语机制的认识 运动序列学习,符合NIDCD的使命,以促进我们对正常和紊乱的理解 改善沟通障碍患者的生活。这项提案还将提供关键的 包括结构神经成像方法和神经退行性言语障碍研究在内的培训 这对于受训者成功过渡到独立研究职业至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hilary Elizabeth Miller其他文献

Hilary Elizabeth Miller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hilary Elizabeth Miller', 18)}}的其他基金

Predictors of Speech Motor Sequence Learning in Neurological Disorders
神经系统疾病中言语运动序列学习的预测因素
  • 批准号:
    10626846
  • 财政年份:
    2022
  • 资助金额:
    $ 4.5万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 4.5万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 4.5万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 4.5万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 4.5万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 4.5万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 4.5万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 4.5万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 4.5万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 4.5万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 4.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了